Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Alyn Hugh MoriceSurinder S BirringJaclyn A SmithLorcan P McGarveyJonathan SchelfhoutAllison Martin NguyenZhi Jin XuWen-Chi WuDavid R MuccinoMandel R SherPublished in: Lung (2021)
ClinicalTrials.gov, NCT02612610; registered November 20, 2015.